Can I Take Glutathione with Zetia (Ezetimibe)?

This article is pending qualified medical review. Nothing here is individualized dosing or diagnostic advice.

Ezetimibe, sold under the brand name Zetia, is an FDA-approved cholesterol absorption inhibitor taken as a 10 mg tablet once daily, usually alongside a statin or on its own for patients who cannot tolerate one. Glutathione is an endogenous antioxidant tripeptide sold as an oral, sublingual, liposomal, or intravenous (IV) supplement. No published trial, case report, or the current FDA prescribing label lists glutathione as an interacting substance with ezetimibe. The more useful question for most readers is not "does an interaction exist" but "does the formulation and dose of glutathione I'm using change the level of caution that's reasonable", because oral glutathione and IV glutathione are pharmacologically different exposures, and the honest answer differs slightly for each.

At standard oral doses, there is no documented pharmacokinetic or pharmacodynamic mechanism by which glutathione would meaningfully change ezetimibe absorption, metabolism, or effect, because ezetimibe is cleared by intestinal and hepatic glucuronidation (UGT1A1/UGT1A3) rather than the cytochrome P450 pathways or transporters that most known supplement interactions involve. IV glutathione delivers much larger systemic doses and has not been specifically studied with ezetimibe, so caution there is based on plausibility rather than documented harm. Readers should treat this as a low-concern combination for oral use and a "disclose and monitor" situation for IV use, pending confirmation from a pharmacist against the current product label.

How ezetimibe works and why its metabolic pathway matters here

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal brush border, which reduces absorption of dietary and biliary cholesterol. After oral dosing it undergoes extensive first-pass conjugation, forming ezetimibe-glucuronide, the active circulating form, primarily through the UGT1A1 and UGT1A3 enzymes. It then cycles through enterohepatic recirculation, which is part of why it has a long enough effective half-life to support once-daily dosing.

Cytochrome P450 enzymes (CYP3A4, CYP2C8, CYP2D6, CYP1A2) play essentially no role in ezetimibe clearance. This matters because most supplement-drug interactions people worry about, St. John's wort with many CYP3A4 substrates, for example, work through CYP enzymes that ezetimibe simply does not use.

The SHARP and IMPROVE-IT trials demonstrated that combining ezetimibe with statins reduces cardiovascular events and LDL cholesterol while maintaining a favorable hepatic safety profile in populations studied. We have not included specific effect sizes and event rates from these trials because citations in earlier versions of this article could not be independently verified against primary sources; healthcare providers should consult the original trial reports or current FDA labeling to obtain accurate figures for patient discussions.

What glutathione is and how the formulation changes the picture

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is synthesized in nearly every human cell from glutamate, cysteine, and glycine. It is used as a supplement for antioxidant support, skin lightening, and general wellness claims, and it also plays a genuine physiological role in hepatic detoxification through glutathione S-transferase enzymes.

Formulation changes systemic exposure substantially:

• Oral glutathione is largely broken down by intestinal gamma-glutamyl transferase and peptidases before it reaches the bloodstream. Small trials of oral supplementation in the 250 to 500 mg/day range have reported modest increases in whole-blood or erythrocyte glutathione, with resulting plasma concentrations that remain low relative to what would be needed to meaningfully affect hepatic enzyme kinetics.
• Liposomal and sublingual glutathione appear to improve absorption somewhat compared with unencapsulated oral forms in small studies, but still fall well short of IV-level exposure.
• Intravenous glutathione, used in some wellness and infusion clinics at gram-level doses per session, bypasses gut breakdown entirely and produces plasma concentrations far higher than any oral route. This is the formulation that deserves more caution when paired with hepatically cleared medications, not because of documented harm with ezetimibe specifically, but because it is the only route where the underlying exposure assumption ("plasma glutathione stays low") no longer holds.

People combine glutathione with cholesterol-lowering therapy for reasons that are biologically plausible but not clinically proven for this specific pairing: oxidative stress is a recognized contributor to atherosclerosis, so some patients reason that an antioxidant might add benefit or offset perceived statin-related stress. Plausibility is not evidence of either benefit or interaction risk, and it should not be treated as either.

Is there a documented interaction? What is known, plausible, and unestablished

No controlled trial, case report, or pharmacovigilance signal specifically pairing glutathione (any formulation) with ezetimibe was identified in the sources available for this review. Absence of a reported signal is not the same as proof of safety across all doses and formulations, particularly for IV use, where specific studies with ezetimibe do not appear to exist.

Absorption. Ezetimibe acts on the NPC1L1 transporter. There is no documented mechanism by which glutathione would compete for or inhibit this transporter.

Metabolism. Ezetimibe is cleared by UGT1A1/UGT1A3 glucuronidation. Oral glutathione produces plasma concentrations well below the range where meaningful UGT inhibition has been described in laboratory studies of glutathione's effect on glucuronidation enzymes generally. This makes a clinically relevant metabolic interaction at oral doses biologically unlikely, though it has not been directly tested with ezetimibe in humans.

Enterohepatic recirculation and excretion. No published human study shows supplemental glutathione altering bile flow or bile acid composition at typical doses. Ezetimibe-glucuronide and glutathione conjugates appear to use different transporter systems for biliary excretion, which lowers the plausibility of competition, but this has not been directly studied as a pair.

Pharmacodynamic effect on LDL. A small pilot study in patients with nonalcoholic fatty liver disease reported that IV glutathione was associated with a reduction in LDL cholesterol independent of lipid-lowering drug use. This is a single, small, open-label study population (NAFLD patients), not a general population on ezetimibe, and the finding needs replication before it should change clinical expectations. If accurate and generalizable, it would suggest an additive rather than opposing effect on LDL, which is not inherently dangerous but is a reason to recheck a lipid panel rather than assume no change occurred.

Liver safety: does combining two hepatically processed compounds add risk?

Both compounds pass through the liver, which is a reasonable thing for a patient to ask about, but shared organ involvement is not the same as shared risk.

Ezetimibe monotherapy has a low reported rate of clinically significant liver enzyme elevation, and the FDA label does not require routine liver function monitoring for ezetimibe alone, though monitoring is advised when it is combined with a statin (verify current monitoring language with a pharmacist or the current prescribing information, since labels are revised over time).

Glutathione is generally regarded as liver-supportive rather than hepatotoxic: it is the substrate hepatocytes use to detoxify reactive oxygen species and electrophilic compounds, and N-acetylcysteine, a glutathione precursor, is the standard antidote for acetaminophen-induced liver injury. This does not mean glutathione supplementation is risk-free at all doses, only that there is no credible mechanism by which it would compound ezetimibe's already-low hepatotoxicity risk at typical supplemental doses.

Checking baseline ALT and AST is still a reasonable precaution, independent of any known interaction, if a patient is:

• Starting IV or high-dose liposomal glutathione (roughly above 500 mg/day) while on any lipid-lowering therapy
• Already on a statin plus ezetimibe combination
• Managing pre-existing liver disease (NAFLD, viral hepatitis, alcohol-related liver disease)
• Using other hepatically active supplements at the same time (for example kava, high-dose niacin, or green tea extract)

A repeat ALT/AST at roughly 6 to 8 weeks after adding a new supplement is a common-sense interval, not a formal guideline requirement specific to this combination.

IV glutathione deserves a separate conversation

IV glutathione, typically dosed from several hundred milligrams to a few grams per session at infusion clinics, has not been studied in combination with ezetimibe in any published trial identified here. The theoretical concern, that a large, rapid conjugation load from IV glutathione could transiently compete for the same glucuronidation cofactors ezetimibe uses, is a plausible pharmacological hypothesis, not a demonstrated effect. If it occurred at all, ezetimibe's long effective half-life would likely blunt any practical impact. This remains unproven and should be described to patients as a theoretical consideration, not a documented risk.

Practical steps for someone receiving IV glutathione while on ezetimibe:

1. Tell the infusing clinician about the ezetimibe (and any statin) by name and dose.
2. Consider a fasting lipid panel 4 to 6 weeks after starting regular infusions to confirm LDL is still at the intended target, not lower than intended.
3. Report new right-upper-quadrant discomfort, jaundice, dark urine, or unusual fatigue to a prescriber rather than assuming it is unrelated.
4. Do not stop or change an ezetimibe dose based solely on starting glutathione, without talking to the prescribing clinician first.

The interactions that actually carry documented clinical weight

To keep the glutathione question in proportion, the ezetimibe interactions with real, label-recognized clinical significance involve:

• Cyclosporine, which increases ezetimibe exposure and requires monitoring, particularly when a statin is also involved.
• Bile acid sequestrants such as cholestyramine, which reduce ezetimibe absorption meaningfully if taken at the same time; the standard practice is to separate dosing by a couple of hours.
• Fenofibrate, which increases ezetimibe exposure to a degree generally not considered clinically significant, though the combination raises gallstone risk considerations independent of ezetimibe levels.

Exact fold-changes and percentages for these interactions are described in the current FDA label rather than restated here as precise numbers, because this draft could not independently verify specific figures against a confirmed primary source. A pharmacist or the current prescribing information should be the reference for exact magnitudes.

Glutathione does not appear on this list in the FDA label or in standard clinical pharmacology references reviewed for this article.

What cardiology and lipid guidelines say about supplements generally

Cardiology and lipid guideline bodies have generally cautioned that supplements should not substitute for proven lipid-lowering pharmacotherapy and that antioxidant supplementation at high doses has, for some antioxidants (notably high-dose vitamin E and beta-carotene in older trials), raised theoretical concerns about blunting the oxidative signaling that partly mediates drug effects. These guidelines do not specifically address glutathione, and no direct guideline statement on glutathione-ezetimibe combination therapy was identified. Readers should not treat this general caution as guideline-level evidence specific to glutathione; it is background context only.

Evidence-boundary summary

Established: Ezetimibe is cleared by UGT1A1/UGT1A3 glucuronidation, not by CYP450 enzymes. No FDA label warning, published trial, or case report identifies a glutathione-ezetimibe interaction.

Biologically plausible but unproven: IV glutathione's large conjugation load could theoretically compete for hepatic glucuronidation cofactors used by ezetimibe; a small NAFLD study suggests IV glutathione may modestly lower LDL independent of lipid drugs, which could theoretically be additive with ezetimibe's effect.

Not established: Any clinically meaningful pharmacokinetic or pharmacodynamic interaction between glutathione, in any formulation, and ezetimibe in general (non-NAFLD) populations. Safety and effect data for high-dose or IV glutathione specifically alongside ezetimibe are absent from the literature reviewed here.

Evidence-status interaction assessment: glutathione and ezetimibe

Monitoring checklist for someone adding glutathione to ezetimibe

• Baseline fasting lipid panel before starting glutathione, if not already recent
• Repeat lipid panel around 6 to 8 weeks after starting, especially with IV or high-dose liposomal glutathione
• Baseline ALT/AST/bilirubin if using IV or high-dose (roughly >500 mg/day) glutathione, or if already on ezetimibe plus a statin
• Full medication and supplement disclosure to the prescriber and to any infusion clinic staff
• Prompt reporting of right-upper-quadrant pain, jaundice, dark urine, unusual fatigue, or new muscle symptoms (muscle symptoms are more relevant if a statin is also in the regimen)
• No self-directed change to ezetimibe dosing based on adding glutathione

When to seek care sooner rather than waiting for a routine follow-up

New jaundice, dark urine, severe abdominal pain, or signs of an allergic reaction after starting any new supplement or infusion warrant prompt medical attention rather than waiting for a scheduled lab draw. Muscle pain or weakness in someone also taking a statin should also be reported promptly, since that combination (not glutathione) is the one with an established myopathy risk pathway.